Kraft A - Search Results

1

Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma.

Skorupa A, Beldner M, Kraft A, Montero AJ. Skorupa A, et al. Among authors: kraft a. Cancer Biol Ther. 2007 Jul;6(7):1015-7. doi: 10.4161/cbt.6.7.4338. Cancer Biol Ther. 2007. PMID: 17611408 Free article.

2

Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis.

Sui M, Xiong X, Kraft AS, Fan W. Sui M, et al. Cancer Biol Ther. 2006 Aug;5(8):1015-21. doi: 10.4161/cbt.5.8.2909. Epub 2006 Aug 18. Cancer Biol Ther. 2006. PMID: 16855376 Free article.

3

Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy.

Xiong X, Sui M, Fan W, Kraft AS. Xiong X, et al. Cancer Biol Ther. 2007 Jul;6(7):1067-73. doi: 10.4161/cbt.6.7.4323. Cancer Biol Ther. 2007. PMID: 17568189 Free article.

4

Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial.

Hayslip J, Chaudhary U, Green M, Meyer M, Dunder S, Sherman C, Salzer S, Kraft A, Montero AJ. Hayslip J, et al. Among authors: kraft a. BMC Cancer. 2007 Dec 3;7:221. doi: 10.1186/1471-2407-7-221. BMC Cancer. 2007. PMID: 18053191 Free PMC article. Clinical Trial.

5

Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer.

Beldner MA, Sherman CA, Green MR, Garrett-Mayer E, Chaudhary U, Meyer ML, Kraft AS, Montero AJ. Beldner MA, et al. Among authors: kraft as. BMC Cancer. 2007 Dec 20;7:231. doi: 10.1186/1471-2407-7-231. BMC Cancer. 2007. PMID: 18096059 Free PMC article. Clinical Trial.

6

PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells.

Zhang F, Beharry ZM, Harris TE, Lilly MB, Smith CD, Mahajan S, Kraft AS. Zhang F, et al. Cancer Biol Ther. 2009 May;8(9):846-53. doi: 10.4161/cbt.8.9.8210. Epub 2009 May 18. Cancer Biol Ther. 2009. PMID: 19276681 Free article.

7

Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade.

Kraft AS, Garrett-Mayer E, Wahlquist AE, Golshayan A, Chen CS, Butler W, Bearden J, Lilly M. Kraft AS, et al. Cancer Biol Ther. 2011 Jul 15;12(2):119-24. doi: 10.4161/cbt.12.2.15723. Epub 2011 Jul 15. Cancer Biol Ther. 2011. PMID: 21532336 Free article. Clinical Trial.

8

In vivo administration of bryostatin 1, a protein kinase C activator, decreases murine resistance to Salmonella typhimurium.

Kraft AS, Adler V, Hall P, Pettit GR, Benjamin WH Jr, Briles DE. Kraft AS, et al. Cancer Res. 1992 Apr 15;52(8):2143-7. Cancer Res. 1992. PMID: 1559218

9

The BH3 mimetic ABT-737 induces cancer cell senescence.

Song JH, Kandasamy K, Zemskova M, Lin YW, Kraft AS. Song JH, et al. Cancer Res. 2011 Jan 15;71(2):506-15. doi: 10.1158/0008-5472.CAN-10-1977. Epub 2010 Nov 16. Cancer Res. 2011. PMID: 21084274 Free PMC article.

10

The 2014 Surgeon General's report: "The health consequences of smoking--50 years of progress": a paradigm shift in cancer care.

Warren GW, Alberg AJ, Kraft AS, Cummings KM. Warren GW, et al. Cancer. 2014 Jul 1;120(13):1914-6. doi: 10.1002/cncr.28695. Epub 2014 Mar 28. Cancer. 2014. PMID: 24687615 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

659 results

Search Page

Filters